NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.2200
-0.0100 (-0.31%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.2300
Open3.3300
Bid3.1300 x 1000
Ask3.2800 x 900
Day's Range3.1655 - 3.3894
52 Week Range2.3400 - 8.6500
Volume511,473
Avg. Volume599,498
Market Cap36.056M
Beta (5Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-2.1610
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
  • GlobeNewswire

    Neovasc Advances New Transfemoral Trans-septal Tiara Design Concept After Further Successful Tests

    VANCOUVER, Jan. 24, 2020 -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter.

  • Neovasc Advances New Transfemoral Trans-Septal Tiara Design Concept After Further Successful Tests
    Newsfile

    Neovasc Advances New Transfemoral Trans-Septal Tiara Design Concept After Further Successful Tests

    Vancouver, British Columbia--(Newsfile Corp. - January 24, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that after further successful acute animal tests conducted earlier this week, a final design concept for the fully retrievable transfemoral trans-septal Tiara™ ("TF/TS Tiara") system, including a ...

  • GlobeNewswire

    Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations in Germany

    At a workshop held January 22, 2020 in Landshut by the Krankenhaus Achdorf, in cooperation with Berlin-Chemie and Neovasc, Dr. Stylianos Pyxaras presented the Reducer as a new treatment option for chronic angina. “We are encouraged by the growing use and satisfaction of physicians with the outcomes of the Reducer Therapy for their patients,” said Fred Colen, President and Chief Executive Officer of Neovasc.

  • Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations in Germany
    Newsfile

    Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations in Germany

    Vancouver, British Columbia--(Newsfile Corp. - January 22, 2020) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ ("Reducer") was featured in three presentations across Germany this month.The presentations included:At the 20th Cardiology Symposium, held January 11, 2020 in Berlin, ...

  • GlobeNewswire

    Updates on Reducer and Tiara Programs Will be Presented at Advanced Cardiovascular Intervention 2020 Meeting

    Neovasc Provides Corporate Update Vancouver, BC, Jan. 21, 2020 -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the.

  • Baystreet

    Stocks in play: Neovasc Inc.

    Announced receipt of an Administrative Acceptance Review Notification for the Company's Premarket Approval ...

  • GlobeNewswire

    Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™

    VANCOUVER, Jan. 15, 2020 -- via NEWMEDIAWIRE – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter.

  • Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer(TM)
    Newsfile

    Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer(TM)

    Vancouver, British Columbia--(Newsfile Corp. - January 15, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") , a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt of an Administrative Acceptance Review Notification for the Company's Premarket Approval application ("PMA") from the U.S. Food and Drug Administration ("FDA") for its Neovasc ...

  • GlobeNewswire

    Neovasc Inc. Investor Update

    “We closed 2019 by doing what we said we would do, when we said we would do it,” said Fred Colen, President and CEO of Neovasc. Thus far approximately 1,300 patients have received the device and results have been encouraging, demonstrating effectiveness in treating refractory angina with a strong safety profile.

  • Neovasc Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market
    Newsfile

    Neovasc Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market

    Vancouver, British Columbia--(Newsfile Corp. - January 6, 2020) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under Nasdaq rules of an aggregate of 1,185,000 series A units ("Series A Units") and 1,241,490 series B units ("Series B Units" and together with the Series A Units, the "Units") at a price of US$4.1351 per Series ...

  • Company News For Jan 2, 2020
    Zacks

    Company News For Jan 2, 2020

    Companies in the news are: NVCN, VIVE, SDRL, UROV

  • GlobeNewswire

    Neovasc Announces $10 Million Registered Direct Offering Priced At-The-Market

    Vancouver, Canada, Jan. 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain institutional investors for the sale of an aggregate of 2,418,322 series A units (“Series A Units”) and series B units (“Series B Units” and together with the Series A Units, the “Units”) at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules for aggregate gross proceeds to the Company of approximately US$10 million, before deducting placement  agent’s fees and estimated expenses of the Offering payable by the Company. Each Series A Unit will consist of one common share of the Company (each, a “Unit Share”) and one warrant (a “Warrant”) to purchase one common share.

  • Neovasc Announces $10 Million Registered Direct Offering Priced At-The-Market
    Newsfile

    Neovasc Announces $10 Million Registered Direct Offering Priced At-The-Market

    Vancouver, British Columbia--(Newsfile Corp. - January 2, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain institutional investors for the sale of an aggregate of 2,418,322 series A units ("Series A Units") and series B units ("Series B Units" and together with the Series A Units, the "Units") at a price of US$4.1351 per Series A Unit and US$4.135 per ...

  • GlobeNewswire

    Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer™

    “This submission marks an important milestone in our effort to bring Reducer to the U.S. market, where it is estimated that there are up to 1.8 million patients with refractory angina,” said Fred Colen, President and Chief Executive Officer of Neovasc.

  • Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer(TM)
    Newsfile

    Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer(TM)

    Vancouver, British Columbia--(Newsfile Corp. - December 31, 2019) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the submission of a Premarket Approval application ("PMA") to the U.S. Food and Drug Administration ("FDA") for its Neovasc Reducer™ ("Reducer") medical device for the treatment ...

  • Newsfile

    Neovasc Reducer(TM) Featured In National Geographic Magazine

    Vancouver, British Columbia--(Newsfile Corp. - December 17, 2019) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured in a special issue titled: "The Future of Medicine" of National Graphic Magazine, published in December 2019. An ...

  • GlobeNewswire

    Neovasc Reducer™ Featured In National Geographic Magazine

    An image of the Reducer was accompanied by a case study of a patient who was implanted with the Reducer. Neovasc’s Medical Director, Prof. Shmuel Banai, MD, Director of the Division of Cardiology and the Head of Interventional Cardiology at the Tel Aviv Medical Center, Tel Aviv, Israel, is also prominently featured.

  • Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019
    Newsfile

    Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019

    Vancouver, British Columbia--(Newsfile Corp. - December 4, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has been selected as a finalist in this year's Fierce Innovation Awards - LifeSciences Edition, a peer reviewed awards program from the publisher of FierceBiotech and ...

  • GlobeNewswire

    Neovasc Named Finalist in Questex’s Fierce Innovation Awards LifeSciences Edition 2019

    Neovasc was recognized as a finalist in the category of Medical Device Innovation. Neovasc was selected as a finalist for its innovative Neovasc Reducer™ (the “Reducer”), a medical device developed for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies.

  • GlobeNewswire

    Neovasc Reducer™ Featured In FOCUS Magazine

    Professor Tommaso Gori, who leads the cardiac catheterization lab at the prestigious University Hospital Mainz, explained to FOCUS readers in the supplement called “Medizinischer Fortschritt” how Reducer therapy helps patients with Chronic Angina Pectoris. Professor Gori commented on the available robust clinical evidence on the safety and efficacy of the Reducer therapy and highlighted that 75% of patients treated with Reducer feel better and experience less chest pain.